Pasireotide
Pasireotide is an FDA-approved multi-receptor somatostatin analog. Pasireotide binds somatostatin receptor subtypes 1, 2, 3 and 5, with markedly higher affinity for subtype 5 than octreotide or lanreotide. Corticotroph adenomas in Cushing disease express subtype 5 predominantly, which is why pasireotide can suppress ACTH where subtype-2-selective analogs do not.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 1047.2 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- subcutaneous, intramuscular
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Somatostatin analog with a broader receptor binding profile than octreotide, approved for Cushing disease and for acromegaly in patients inadequately controlled by surgery or other somatostatin analogs.
Peptide Library's Pasireotide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous, intramuscular
- Reconstitution Guide
- —
Sequence & molecular data
| Molecular formula | C58H66N10O9 |
|---|---|
| Molecular weight | 1047.2 g/mol |
| PubChem CID | 9941444 |
| FDA UNII | 98H1T17066 |
| ChEMBL | CHEMBL3349607 |
| DrugBank | DB06663 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Pasireotide binds somatostatin receptor subtypes 1, 2, 3 and 5, with markedly higher affinity for subtype 5 than octreotide or lanreotide. Corticotroph adenomas in Cushing disease express subtype 5 predominantly, which is why pasireotide can suppress ACTH where subtype-2-selective analogs do not. The same broad receptor engagement contributes to a higher incidence of hyperglycaemia, driven by reduced insulin and incretin secretion.
Regulatory & research status
Pasireotide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Pasireotide: frequently asked questions
What is Pasireotide?
Somatostatin analog with a broader receptor binding profile than octreotide, approved for Cushing disease and for acromegaly in patients inadequately controlled by surgery or other somatostatin analogs.
How does Pasireotide work?
Pasireotide binds somatostatin receptor subtypes 1, 2, 3 and 5, with markedly higher affinity for subtype 5 than octreotide or lanreotide. Corticotroph adenomas in Cushing disease express subtype 5 predominantly, which is why pasireotide can suppress ACTH where subtype-2-selective analogs do not.
Is Pasireotide FDA approved?
Yes. Pasireotide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Pasireotide?
Compounds most often compared with Pasireotide include Octreotide, Lanreotide, Human Growth Hormone (Somatropin) and Lonapegsomatropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Pasireotide-a novel somatostatin receptor ligand after 20 years of use — Rev Endocr Metab Disord, 2022External reference
- Pasireotide in Acromegaly: A Review — Drugs, 2015External reference
- Pasireotide, 2012External reference
- Pasireotide, 2006External reference
- Pasireotide as first line medical therapy for selected patients with acromegaly — Pituitary, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Pasireotide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Pasireotide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →